|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
Ranbaxy Laboratories (2008)
|
|
gptkbp:CEO
|
gptkb:Sunao_Manabe
|
|
gptkbp:collaboratesWith
|
gptkb:AstraZeneca
gptkb:Merck_&_Co.
|
|
gptkbp:country
|
gptkb:Japan
|
|
gptkbp:divested
|
Ranbaxy Laboratories (2014)
|
|
gptkbp:ESRB_rating
|
included in FTSE4Good Index
|
|
gptkbp:focusArea
|
oncology
cardiovascular diseases
rare diseases
|
|
gptkbp:formedByMergerOf
|
gptkb:Sankyo_Co.,_Ltd.
gptkb:Daiichi_Pharmaceutical
|
|
gptkbp:founded
|
2005
|
|
gptkbp:globalPresence
|
operates in over 20 countries
|
|
gptkbp:hasCompany
|
yes
|
|
gptkbp:hasResearchCenter
|
gptkb:Munich,_Germany
gptkb:Gothenburg,_Sweden
gptkb:Shinagawa,_Tokyo
|
|
gptkbp:headquarters_location
|
gptkb:Tokyo,_Japan
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Daiichi Sankyo Group
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:keyPerson
|
gptkb:Sunao_Manabe
|
|
gptkbp:listedOn
|
gptkb:Nikkei_225
|
|
gptkbp:marketCap
|
over $50 billion (2023)
|
|
gptkbp:member
|
gptkb:Japan_Pharmaceutical_Manufacturers_Association
|
|
gptkbp:notableContributor
|
precision medicine
immuno-oncology
antibody-drug conjugates
|
|
gptkbp:notableProduct
|
gptkb:Enhertu
gptkb:Edoxaban
gptkb:Olmesartan
|
|
gptkbp:numberOfEmployees
|
over 15,000
|
|
gptkbp:parentCompany
|
Daiichi Sankyo Co., Ltd.
|
|
gptkbp:products
|
pharmaceutical drugs
|
|
gptkbp:revenue
|
over 1 trillion yen (2023)
|
|
gptkbp:stockExchange
|
gptkb:Tokyo_Stock_Exchange
|
|
gptkbp:stockSymbol
|
4568
|
|
gptkbp:subsidiary
|
gptkb:Daiichi_Sankyo,_Inc._(USA)
gptkb:Daiichi_Sankyo_Europe_GmbH
|
|
gptkbp:website
|
https://www.daiichisankyo.com/
|
|
gptkbp:bfsParent
|
gptkb:Daiichi_Sankyo
|
|
gptkbp:bfsLayer
|
6
|